Tonix Pharmaceuticals Holding Corp (TNXP) - Total Liabilities
Based on the latest financial reports, Tonix Pharmaceuticals Holding Corp (TNXP) has total liabilities worth $32.02 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore TNXP strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Tonix Pharmaceuticals Holding Corp - Total Liabilities Trend (2008–2025)
This chart illustrates how Tonix Pharmaceuticals Holding Corp's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see TNXP total assets.
Tonix Pharmaceuticals Holding Corp Competitors by Total Liabilities
The table below lists competitors of Tonix Pharmaceuticals Holding Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Toro Ltd
LSE:TORO
|
UK | €131.05 Million |
|
Sinar Mas Multiartha Tbk
JK:SMMA
|
Indonesia | Rp89.66 Trillion |
|
Verkkokauppa.com Oyj
HE:VERK
|
Finland | €140.74 Million |
|
Core Molding Technologies Inc
NYSE MKT:CMT
|
USA | $69.96 Million |
|
SCH Group Bhd
KLSE:0161
|
Malaysia | RM740.25 Million |
|
JINSUNG T.E.C. Inc
KQ:036890
|
Korea | ₩216.64 Billion |
|
Metsa Board Oyj A
HE:METSA
|
Finland | €1.03 Billion |
|
ÜSTRA Hannoversche Verkehrsbetriebe Aktiengesellschaft
F:HVB
|
Germany | €279.51 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Tonix Pharmaceuticals Holding Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See TNXP equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tonix Pharmaceuticals Holding Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tonix Pharmaceuticals Holding Corp (2008–2025)
The table below shows the annual total liabilities of Tonix Pharmaceuticals Holding Corp from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $32.02 Million | +37.24% |
| 2024-12-31 | $23.33 Million | -52.32% |
| 2023-12-31 | $48.93 Million | +164.38% |
| 2022-12-31 | $18.51 Million | -16.57% |
| 2021-12-31 | $22.18 Million | +110.56% |
| 2020-12-31 | $10.54 Million | +104.92% |
| 2019-12-31 | $5.14 Million | +93.63% |
| 2018-12-31 | $2.65 Million | +24.18% |
| 2017-12-31 | $2.14 Million | -0.51% |
| 2016-12-31 | $2.15 Million | -68.19% |
| 2015-12-31 | $6.76 Million | +95.83% |
| 2014-12-31 | $3.45 Million | +55.13% |
| 2013-12-31 | $2.22 Million | +91.97% |
| 2012-12-31 | $1.16 Million | -59.77% |
| 2011-12-31 | $2.88 Million | +27841.38% |
| 2010-12-31 | $10.30K | +943.02% |
| 2009-12-31 | $988.00 | -67.07% |
| 2008-12-31 | $3.00K | -- |
About Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and T… Read more